1. Keynoter Florida Keys
2. Keynote For Mac

was established in 1994 as a privately-owned collection agency.

For maximum control, however, Keynote desktop is the way to go. Tips to Make Your First Keynote Presentation a Standout. Even the most novice of Keynote users can make something stunning in just a few minutes. Well, if you haven’t noticed, Keynote’s built-in themes already look great. Following the keynote attend GTC sessions for a deep dive on technologies transforming our world presented by prestigious researchers, including Turing Award winners, business leaders, and industry pioneers. With over 1,600 sessions to explore – and free to attend – don’t miss the chance to discover what comes next. Easily create gorgeous presentations with Keynote, featuring powerful yet easy-to-use tools and dazzling effects that will make you a very hard act to follow. The Theme Chooser lets you skim through an impressive collection of 30 new and updated Apple-designed themes. Keynote is the most powerful presentation app ever designed for a mobile device. Built from the ground up for iPad, iPhone, and iPod touch, it makes creating a world-class presentation — complete with animated charts and cinematic transitions — as simple as touching and tapping. Compared with PowerPoint, Keynote is a relatively recent software introduced in 2003 — but is such a big deal if in whole the app is awesome? Apple Keynote Get from App Store.

Keynote has perfected a proven style for collecting Medical, Consumer and Commercial Accounts.

Contact us Today

Maintains a High Standard of Business Ethics
to which all Personnel are required to Adhere to.

Contact us Today

Has an Outstanding Reputation, Cutting-Edge Technology and a High Degree of Professionalism.

To discuss your collection needs, Contact Us Today.

Free Consultation

Established in 1996, Keynote Consulting Inc. is a licensed and bonded Illinois collection agency. As a family owned & operated business our reputation and legacy are of the upmost importance to us. With that in mind we hold ourselves to the highest standards. By utilizing our comprehensive set of services to help our clients maximize the liquidity of their portfolios we have become nationally recognized as an industry leader in compliance and execution. Our staff is highly experienced and trained for excellence. We are adept and equipped to handle any of our clients’ accounts receivable needs.

Often, collection agencies are “revolving door” businesses. Employees seem to come and go with regularity, and there is little continuity between the collector and your customer. At Keynote Consulting, Inc. we hire only experienced professionals who dedicate themselves to working with people to resolve their pressing financial matters from start to finish. No matter which Keynote employee answers the call, your customers will be speaking with a staff member who has the knowledge and experience to effectively provide you with the best possible result.

Do You Need a Collection Agency?

Any business small or large may have a need for assistance in accounts receivable. Having unpaid receivables impacts any business, but growing businesses especially. Keynote happily accepts portfolios of any size.

Keynote specializes in all sectors of medical and consumer debt. We happily work with medical billing companies as well as directly with doctor’s offices. We also work with credit unions, financing companies, and property management companies.

Testimonials

There is no shortage of collection agencies out there, but finding a group that is regimented, honest, customer service forward and productive like Keynote is not easy.

Keynote has been collecting on our delinquent accounts for the past 15 years or more.

When we opened Webster Dental nearly 30 years ago, I went to various firms for all my delinquent account needs, and note have been as effective as keynote.

Over the years they have exemplified consistency and professionalism. We are very pleased with the lever of service they provide.

Over the past 11 years Keynote has been dedicated to our debt and judgment recovery.

We have been using the collection services of Keynote Consulting since 2005

Keynoter Florida Keys

Inclusion Criteria:

• Pathological diagnosis of NSCLC confirmed at surgery, any histology. Participants with two synchronous primary non-small cell lung cancers are excluded from the study
• Union for International Cancer Control (UICC) v7 Stage IB with T ≥ 4 cm, II-IIIA NSCLC after complete surgical resection with resection margins proved microscopically free of disease (R0). Carcinoma in situ can be present at the bronchial margin
• Available tumor sample obtained at surgical resection for programmed cell death ligand-1 (PD-L1) Immunohistochemistry (IHC) expression assessment
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• Adequate organ function performed within 10 days of treatment initiation
• Female participants of childbearing potential must have a negative urine or serum pregnancy test at screening (within 72 hours of first infusion of study medication). If the urine test cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the participant to be eligible
• Female participants of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity starting with the first infusion of study treatment through 120 days after the last infusion of study treatment
• Female participants who are breast feeding must discontinue nursing prior to the first infusion of study medication and until 120 days after the last infusion study treatment
• Male participants must agree to use an adequate method of contraception starting with the first infusion of study treatment through 120 days after the last infusion of study treatment
• Absence of severe comorbidities that in the opinion of the Investigator might hamper the participation to the study and/or the treatment administration
• No prior or planned neo-adjuvant or adjuvant radiotherapy and/or neo-adjuvant chemotherapy for the current malignancy is allowed

Exclusion Criteria:

Keynote For Mac

• Evidence of disease at clinical examination and/or baseline radiological assessment as documented by contrast enhanced chest/upper abdomen CT scan, brain CT/MRI and clinical examination
• More than 4 cycles of adjuvant therapy
• Prior treatment with anti-programmed cell death (anti-PD)-1, anti-PD ligand-1/2, anti-CD137, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulators or any other immune-modulating agents
• Live vaccine within 30 days prior to the first infusion of study treatment
• Current participation or treatment with an investigational agent or use of an investigational device within 4 weeks of the first infusion of study treatment
• History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive). No known active Hepatitis B or C
• Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 3 days prior to the first infusion of study treatment
• History of interstitial lung disease or (non-infectious) pneumonitis that required oral or IV steroids (other than COPD exacerbation) or current pneumonitis
• Active autoimmune disease that has required systemic treatment in past 2 years
• History of a hematologic or primary solid tumor malignancy, unless in remission for at least 5 years with the exception of pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the cervix
• Previous allogeneic tissue/solid organ transplant
• Active infection requiring therapy
• Surgery- or chemotherapy-related toxicity (non-hematological) not resolved to Grade 1 with the exception of alopecia, fatigue, neuropathy and lack of appetite /nausea
• Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last infusion of study treatment
• Participant will not be eligible if the participant is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective site Review Board approval is given allowing exception to this criterion for a specific participant